BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1607922)

  • 1. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
    Robert J; Armand JP; Huet S; Klink-Alakl M; Recondo G; Hurteloup P
    J Clin Oncol; 1992 Jul; 10(7):1183-90. PubMed ID: 1607922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
    J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
    Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
    J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.
    Mross K; Mayer U; Hamm K; Burk K; Hossfeld DK
    Eur J Clin Pharmacol; 1990; 39(5):507-13. PubMed ID: 2076745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
    Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
    J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.
    Robert J; David M; Huet S; Chauvergne J
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1289-94. PubMed ID: 3181250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
    Robert J; Monnier A; Poutignat N; Hérait P
    Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia.
    Kreis W; Rottach C; Budman DR; Chan K; Schulman P; Allen SL; Weiselberg L; Vinciguerra V
    Cancer Res; 1988 Oct; 48(19):5580-4. PubMed ID: 3166400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).
    Dodion P; Davis TA; Rozencweig M; Crespeigne N; Kenis Y; Bachur NR
    Invest New Drugs; 1985; 3(4):361-8. PubMed ID: 4086243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
    Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.
    Jacquet JM; Bressolle F; Galtier M; Bourrier M; Donadio D; Jourdan J; Rossi JF
    Cancer Chemother Pharmacol; 1990; 27(3):219-25. PubMed ID: 2265458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
    Hochster H; Liebes L; Wadler S; Oratz R; Wernz JC; Meyers M; Green M; Blum RH; Speyer JL
    J Natl Cancer Inst; 1992 Nov; 84(22):1725-30. PubMed ID: 1433357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
    Miller AA; Schmidt CG
    Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.
    Rahman A; Treat J; Roh JK; Potkul LA; Alvord WG; Forst D; Woolley PV
    J Clin Oncol; 1990 Jun; 8(6):1093-100. PubMed ID: 2348224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.
    Piscitelli SC; Rodvold KA; Rushing DA; Tewksbury DA
    Clin Pharmacol Ther; 1993 May; 53(5):555-61. PubMed ID: 8387903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.